yervoy
bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antinavikiniai vaistai - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4. yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 ir 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.
adrenalina s.a.l.f.
actiofarma, uab - adrenalinas - injekcinis ar infuzinis tirpalas - 1 mg/ml - epinephrine
adrenalinum pph [adrenalinum wzf polfa]
zakłady farmaceutyczne polpharma s.a. - adrenalino tartratas - injekcinis ar infuzinis tirpalas - 1 mg/ml - epinephrine
cerezyme
sanofi b.v. - imigliucerazė - gošė liga - kiti virškinimo trakto ir metabolizmo produktus, - cerezyme (imigliucerazės) yra skirtas naudoti kaip ilgalaikės fermentų terapijai pacientams, kuriems yra diagnozuota ne neuronopathic (tipas 1) arba lėtinis neuronopathic (3 tipas) gošė liga, eksponuoti kliniškai reikšmingo nonneurological ligos pasireiškimus. ne neurologiniai požymiai gaucher liga gali apimti vieną ar daugiau iš šių sąlygų:anemija po atskirties ir kitų priežasčių, pvz., geležies deficiencythrombocytopeniabone liga po atskirties ir kitų priežasčių, tokių kaip vitamino d deficiencyhepatomegaly ar splenomegaly.
oxyglobin
opk biotech netherlands bv - hemoglobinas glutamer-200 (galvijų) - kraujo pakaitalai ir infuziniai tirpalai. - Šunys - oksiglobinas užtikrina deguonies palaikymą šunims, pagerinantiems klinikinius anemijos požymius mažiausiai 24 valandas, nepriklausomai nuo pagrindinės būklės.
qutenza
grunenthal gmbh - kapsaicinas - neuralgija - anestezijos - qutenza vartojamas gydyti dėl periferinės neuropatijos malšinti suaugusiesiems arba atskirai arba kartu su kitais vaistais nuo skausmo.
carbetocin pharmidea
sia pharmidea - karbetocinas - injekcinis tirpalas - 100 µg/ml - carbetocin
olopeg
mip pharma gmbh - makrogolis 4000/natrio citratas/citrinų rūgštis/natrio chloridas/kalio chloridas - koncentratas geriamajam tirpalui - 525 mg/19,5 mg/16,5 mg/7,3 mg/1,9 mg/ml - macrogol
tolirasim
aflofarm farmacja polska sp. z o.o. - lizinoprilis/torazemidas - tabletės - 20 mg/10 mg; 10 mg/10 mg; 10 mg/5 mg; 20 mg/5 mg - lisinopril and diuretics
tranxene
neuraxpharm arzneimittel gmbh - dikalio klorazepatas - kietosios kapsulės - 5 mg; 10 mg - potassium clorazepate